Adaptive Biotechnologies Beats Q2 Revenue, Raises MRD Guidance, and Announces CSO Transition
ADPT has more than doubled off its 52-week low of $9.955.
Summary
Adaptive Biotechnologies posted Q2 2026 revenue of $71.6M, exceeding estimates, raised its full-year MRD revenue guidance, and announced the transition of its Chief Scientific Officer to a consulting role.
Key Events · Earnings and Guidance · ADPT
-
Q2 Revenue Beat
Revenue reached $71.6M, a 22% increase year-over-year, topping the $65.9M consensus. MRD revenue surged 33% to $66.2M, now accounting for 92% of total revenue.
-
MRD Guidance Raised
Full-year 2026 MRD revenue guidance was lifted to $268M–$278M, implying 26–31% growth, up from the prior range of $260M–$270M.
-
Near Breakeven Adjusted EBITDA
Driven by revenue growth and cost discipline, the Adjusted EBITDA loss narrowed to $0.7M from $7.2M a year ago.
-
CSO Transition
Chief Scientific Officer and co-founder Harlan Robins will move to a strategic consultant role, supporting MRD R&D and the Immune Medicine separation.
Analysis · ADPT · Life Sciences
A strong second quarter saw Adaptive Biotechnologies deliver revenue of $71.6M, surpassing the $65.9M consensus, while MRD revenue grew 33%. Bolstered by this momentum, the company raised its full-year MRD guidance to $268M–$278M, implying 26–31% growth, and nearly reached breakeven on an Adjusted EBITDA basis. These results underscore the MRD business's trajectory following the recent $345M convertible note raise and the planned separation of the Immune Medicine unit. In a governance update, CSO and co-founder Harlan Robins will transition to a consulting role—a move framed as a planned step tied to the restructuring.
At the time of this filing, ADPT was trading at $22.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $9.96 to $23.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.